Key Highlights
- The FDA granted Accelerated Approval to Nelkarmi for previously treated ALK-positive non-small cell lung cancer.
- The approval came ahead of the original FDA target action date of November 27, 2026.
- In patients previously treated with alectinib alone, the confirmed overall response rate was 49%.
- The most common adverse reactions were hepatotoxicity, musculoskeletal pain, constipation and dysgeusia.
GSK plc (NYSE:GSK) announced that the US Food and Drug Administration has granted accelerated approval to Nelkarmi, known generically as neladalkib, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have previously received therapy. The approval came ahead of the FDA’s original target action date of November 27, 2026.
The company said this is its second new medicine approved in lung cancer this year. The approval follows the FDA’s Breakthrough Therapy and Orphan Drug designations for the product.
Eligible Patients and the Basis for Approval
The approval covers patients who have received one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs together with platinum-based chemotherapy. The approval is based on results from the phase I/II ALKOVE-1 trial.
For patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate was 49%, or 33 of 67 patients. Among responders, 76% had a response lasting six months or longer and 52% had one lasting 12 months or longer, as assessed by blinded independent central review.
Intracranial Activity and Safety
In patients with baseline central nervous system metastases, the intracranial response rate was 55% in those previously treated with alectinib alone, with 25% complete responses. In patients who had received two or more prior ALK TKIs and chemotherapy, the intracranial response rate was 26%, including 11% complete responses.
The most common adverse reactions occurring in at least 20% of patients were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. Permanent discontinuation due to adverse reactions occurred in 5% of patients, most often because of hepatotoxicity.
Company Positioning and Clinical Commentary
GSK chief scientific officer Tony Wood said Nelkarmi was designed to address key challenges of ALK-positive lung cancer, including resistance mutations, brain involvement and tolerability. He said these patients are often younger and can remain on treatment for years.
Alice Shaw, an ALKOVE-1 investigator at Dana-Farber Cancer Institute, said that balancing disease control with long-term tolerability remains a significant challenge, and that the approval gives patients an important new option. The release did not describe pricing or launch timing.
Final Word
Nelkarmi’s accelerated approval gives US patients with previously treated ALK-positive lung cancer a new targeted option, with response rates reported from a phase I/II study. The FDA action arrived ahead of its target date and follows two expedited designations.
Because the approval is accelerated, its continued status depends on confirmatory evidence that GSK must provide. The announcement did not include sales expectations or the outcome of any confirmatory trial.






Please wait processing your request...